Table 1.
Baseline demographics, status of coronary artery disease determined by coronary CT angiography and levels of biomarkers in the 54 patients undergoing repeat coronary CT angiography and a complete set of biomarkers vs. the remaining patients from the ROMICAT trial.
| Variables | Follow-up cohort (n=54) | Cohort without follow-up CCTA or incomplete biomarkers (n=314) | p-value |
|---|---|---|---|
| Median follow-up time (months) | 23.9 (20.5–24.9) | N/A | |
| Age (years) | 54.0 ± 12.1 | 53.6 ± 11.7 | .42 |
| men | 59% (32) | 62% (194) | .72 |
| Framingham Risk Score | 8.0 ± 7.8 | 7.0 ± 6.9 | .35 |
| Diabetes mellitus | 3 (6%) | 37 (12%) | .17 |
| Hypertension | 22 (41%) | 123 (39%) | .83 |
| Hyperlipidemia | 28 (52%) | 107 (34%) | .01 |
| Smoker | 10 (19%) | 83 (26%) | .22 |
| Fam. HxCAD | 15 (28%) | 74 (24%) | .50 |
| BMI (kg/m2) | 30.5 ± 6.8 | 28.7 ± 5.8 | .45 |
| ACS at index visit | 15% (8) | 7% (23) | .07 |
| ACS during follow-up | 0 | N/A | |
| CAD: any plaque | 61% (33) | 48% (152) | .11 |
| CAD: any stenosis | 17% (9) | 8% (25) | .07 |
| CAD: calcified plaque | 50% (27) | 45% (141) | .55 |
| hs-TnT (ng/L) | 3.46 (1.17–7.32) | 5.58 (2.82–8.69) | .03 |
| hs-CRP (mg/L) | 2.10 (0.95–4.20) | 1.29 (0.56–2.67) | .01 |
BMI, body mass index; CAD, coronary artery disease; CCTA, coronary CT angiography; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; ROMICAT, Rule Out Myocardial Infarction using Computer Assisted Tomography; SD, standard deviation.
Values are presented as absolute numbers with percentages or mean SD. The Framingham Risk Score and the levels of bio markers are presented as median (interquartile range).